NVST vs DHR vs HOLX vs BDX vs TMO

For growth investors, Envista Holdings Corp (NVST) is the stronger pick with 8.

3% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Becton, Dickinson and Company (BDX) offers the better valuation at 25. 6x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 25.

6x versus Envista Holdings Corp at 86. 6x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 72x versus Danaher Corporation's 33. 47x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +16. 8%, compared to -46. 5% for Envista Holdings Corp (NVST). Over 10 years, the gap is even starker: TMO returned +222. 6% versus NVST's -13. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus Envista Holdings Corp's 1. 63β — meaning NVST is approximately 260% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Envista Holdings Corp (NVST) is pulling ahead at 8.

3% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Envista Holdings Corp grew EPS 104. 3% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, BDX leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Thermo Fisher Scientific Inc.

(TMO) is the more profitable company, earning 15. 1% net margin versus 1. 7% for Envista Holdings Corp — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DHR leads at 20. 9% versus 8. 3% for NVST. At the gross margin level — before operating expenses — HOLX leads at 61. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 72x versus Danaher Corporation's 33. 47x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 11. 9x forward P/E versus 20. 3x for Danaher Corporation — 8. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 44. 3% to $247. 00.

In this comparison, BDX (2.

8% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. NVST, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

62), 2. 8% yield). Envista Holdings Corp (NVST) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BDX: +76. 4%, NVST: -13. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

DHR, BDX pay a dividend while NVST, HOLX, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.